Korro Bio, Inc. - Asset Resilience Ratio
Korro Bio, Inc. (KRRO) has an Asset Resilience Ratio of 28.47% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Korro Bio, Inc. total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2025)
This chart shows how Korro Bio, Inc.'s Asset Resilience Ratio has changed over time. See cash generation quality of Korro Bio, Inc. to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Korro Bio, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Korro Bio, Inc. total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $52.27 Million | 28.47% |
| Total Liquid Assets | $52.27 Million | 28.47% |
Asset Resilience Insights
- Very High Liquidity: Korro Bio, Inc. maintains exceptional liquid asset reserves at 28.47% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Korro Bio, Inc. Industry Peers by Asset Resilience Ratio
Compare Korro Bio, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX |
Biotechnology | 4.91% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 16.06% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Seegene Inc
KQ:096530 |
Biotechnology | 24.96% |
Annual Asset Resilience Ratio for Korro Bio, Inc. (2019–2025)
The table below shows the annual Asset Resilience Ratio data for Korro Bio, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 46.99% | $53.33 Million | $113.51 Million | +15.85pp |
| 2024-12-31 | 31.14% | $70.45 Million | $226.24 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $221.66 Million | -- |
| 2022-12-31 | 25.65% | $18.91 Million | $73.74 Million | -1.90pp |
| 2021-12-31 | 27.55% | $51.07 Million | $185.36 Million | +19.85pp |
| 2019-12-31 | 7.70% | $17.20 Million | $223.22 Million | -- |
About Korro Bio, Inc.
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate … Read more